DE60334460D1 - Antikörper spezifisch für das tau-protein des zentralen nervensystems - Google Patents

Antikörper spezifisch für das tau-protein des zentralen nervensystems

Info

Publication number
DE60334460D1
DE60334460D1 DE60334460T DE60334460T DE60334460D1 DE 60334460 D1 DE60334460 D1 DE 60334460D1 DE 60334460 T DE60334460 T DE 60334460T DE 60334460 T DE60334460 T DE 60334460T DE 60334460 D1 DE60334460 D1 DE 60334460D1
Authority
DE
Germany
Prior art keywords
nervous system
central nervous
antibodies specific
tau protein
tau
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60334460T
Other languages
English (en)
Inventor
Hideto Ohno
Koichi Ishiguro
Masaki Imagawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LSI Medience Corp
Original Assignee
LSI Medience Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LSI Medience Corp filed Critical LSI Medience Corp
Application granted granted Critical
Publication of DE60334460D1 publication Critical patent/DE60334460D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/962—Prevention or removal of interfering materials or reactants or other treatment to enhance results, e.g. determining or preventing nonspecific binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
    • Y10T436/25125—Digestion or removing interfering materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
DE60334460T 2002-08-14 2003-08-14 Antikörper spezifisch für das tau-protein des zentralen nervensystems Expired - Lifetime DE60334460D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002236472 2002-08-14
PCT/JP2003/010340 WO2004016655A1 (ja) 2002-08-14 2003-08-14 中枢性タウ蛋白質特異的抗体

Publications (1)

Publication Number Publication Date
DE60334460D1 true DE60334460D1 (de) 2010-11-18

Family

ID=31884413

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60334460T Expired - Lifetime DE60334460D1 (de) 2002-08-14 2003-08-14 Antikörper spezifisch für das tau-protein des zentralen nervensystems

Country Status (7)

Country Link
US (1) US7442516B2 (de)
EP (1) EP1535930B1 (de)
JP (1) JP4393382B2 (de)
AU (1) AU2003257850A1 (de)
DE (1) DE60334460D1 (de)
ES (1) ES2352668T3 (de)
WO (1) WO2004016655A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US8497072B2 (en) 2005-11-30 2013-07-30 Abbott Laboratories Amyloid-beta globulomer antibodies
PL1954718T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Przeciwciała skierowane przeciwko A globulomerowi, ich reszty wiążące antygeny, odpowiednie hybrydomy, kwasy nukleinowe, wektory, komórki gospodarze, sposoby wytwarzania tych przeciwciał, kompozycje zawierające te przeciwciała, zastosowania tych przeciwciał i sposoby stosowania tych przeciwciał
US20080003693A1 (en) * 2006-06-12 2008-01-03 Great Basin Scientific, Inc. Methods and materials for detecting frameshift mutations
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2486928A1 (de) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Verfahren zur Behandlung von Amyloidosen
CA2692039C (en) * 2007-06-13 2019-07-02 Research Development Foundation Methods for treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating crf receptor signaling
WO2009097425A2 (en) * 2008-01-29 2009-08-06 Spring Bioscience Corporation Method for detecting truncated molecules
RU2581020C2 (ru) * 2009-12-22 2016-04-10 Селлдекс Терапьютикс, Инк. Композиции вакцин
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
WO2012024187A1 (en) 2010-08-14 2012-02-23 Abbott Laboratories Amyloid-beta binding proteins
US20130295021A1 (en) 2010-10-11 2013-11-07 Feng Chen Human anti-tau antibodies
WO2012142301A2 (en) 2011-04-12 2012-10-18 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patients recovery from a brain injury
RU2668159C2 (ru) 2012-07-03 2018-09-26 Вашингтон Юниверсити Антитела против тау
WO2014011972A1 (en) * 2012-07-13 2014-01-16 Bristol-Myers Squibb Company Tau immunoassay
PE20150646A1 (es) 2012-08-16 2015-05-21 Ipierian Inc Metodos de tratamiento de una tauopatia
US9200068B2 (en) 2012-12-18 2015-12-01 Regents Of The University Of Minnesota Compositions and methods related to tauopathy
MX2015008024A (es) 2012-12-21 2016-08-08 Biogen Int Neuroscience Gmbh Anticuerpos anti-tau humanos.
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
SG10201707855YA (en) 2013-03-13 2017-10-30 Prothena Biosciences Ltd Tau immunotherapy
WO2014160647A1 (en) * 2013-03-24 2014-10-02 The Washington University Method for amyloid beta sample processing
TWM474138U (zh) * 2013-06-18 2014-03-11 磁量生技股份有限公司 一種檢測阿茲海默症的系統
WO2015007192A1 (en) * 2013-07-18 2015-01-22 The University Of Hong Kong Methods for classifying pleural fluid
PT3083680T (pt) 2013-12-20 2020-03-17 Hoffmann La Roche Anticorpos humanizados anti-tau(ps422) e métodos de utilização
NZ630610A (en) * 2014-02-14 2019-05-31 Ipierian Inc Tau peptides, anti-tau antibodies, and methods of use thereof
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
TWI734975B (zh) 2014-06-27 2021-08-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
BR112017006419A2 (pt) 2014-09-30 2017-12-19 Univ Washington medições cinéticas de tau
JO3576B1 (ar) 2015-02-26 2020-07-05 Lilly Co Eli أجسام مضادة لـ tau واستخداماتها
ES2809728T3 (es) 2015-06-24 2021-03-05 Hoffmann La Roche Anticuerpos anti-tau(pS422) humanizados y procedimientos de uso
JOP20200228A1 (ar) 2015-12-21 2017-06-16 Novartis Ag تركيبات وطرق لخفض تعبير البروتين tau
CN109415432B (zh) 2016-05-02 2022-07-08 普罗塞纳生物科学有限公司 Tau免疫疗法
PE20190261A1 (es) 2016-05-02 2019-02-25 Prothena Biosciences Ltd Anticuerpos que reconocen tau
EP3496750A2 (de) 2016-08-09 2019-06-19 Eli Lilly and Company Kombinationstherapie
MA47499A (fr) 2017-02-17 2019-12-25 Denali Therapeutics Inc Anticorps anti-tau et leurs procédés d'utilisation
EP3585892B8 (de) * 2017-02-27 2022-07-13 Translate Bio, Inc. Verfahren zur reinigung von messenger-rna
BR112019022906A2 (pt) 2017-05-02 2020-05-26 Prothena Biosciences Limited Anticorpos que reconhecem tau
US20200408781A1 (en) 2018-03-05 2020-12-31 Gallen Triana-Baltzer Assays to detect neurodegeneration
CN112543648A (zh) 2018-07-31 2021-03-23 伊莱利利公司 组合疗法
CU20210073A7 (es) 2019-03-03 2022-04-07 Prothena Biosciences Ltd Anticuerpos que se unen dentro de la región de unión a microtúbulos de tau definida por cdrs
EP4271708A1 (de) 2020-12-29 2023-11-08 Neurimmune AG Menschliche anti-tau-antikörper
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003369A1 (en) * 1991-08-01 1993-02-18 Voorheis Paul H Diagnostic method for alzheimer's disease
JP3992729B2 (ja) * 1993-12-21 2007-10-17 インノジェネティクス・エヌ・ブイ Ｐｈｆ−タウに特異的なモノクローナル抗体、これらを分泌するハイブリドーマ、これらの抗体による抗原認識及びこれらの応用
AU710952B2 (en) * 1994-07-29 1999-09-30 Innogenetics N.V. Monoclonal antibodies specific for an epitope of a particular subclass or form of phosphorylated tau, hybridomas secreting them, antigen recognition of these antibodies and their applications
WO1997034145A1 (fr) * 1996-03-13 1997-09-18 Mitsubishi Chemical Corporation Anticorps a proteine tau antiphosphorylee et procede de detection de la maladie d'alzheimer l'utilisant
JP4624559B2 (ja) * 1998-09-08 2011-02-02 イノジェネティックス・ナムローゼ・フェンノートシャップ 初期ｃｎｓダメージのマーカーとしてのタウ
US6136963A (en) * 1999-07-27 2000-10-24 Heska Corporation Parasitic helminth DiAg2 nucleic acid molecules, and uses thereof
US6589746B1 (en) * 1999-10-21 2003-07-08 University Of Cincinnati Method of detecting axonally-derived protein tau in patients with traumatic CNS injury
BR0107851A (pt) * 2000-01-24 2002-10-29 Innogenetics Nv Diagnose de tauopatia
JP2002040023A (ja) * 2000-07-28 2002-02-06 Mitsubishi Chemicals Corp アルツハイマー病の検出方法

Also Published As

Publication number Publication date
EP1535930A1 (de) 2005-06-01
ES2352668T3 (es) 2011-02-22
WO2004016655A1 (ja) 2004-02-26
AU2003257850A1 (en) 2004-03-03
EP1535930A4 (de) 2005-09-21
EP1535930B1 (de) 2010-10-06
JP4393382B2 (ja) 2010-01-06
US7442516B2 (en) 2008-10-28
US20050181460A1 (en) 2005-08-18
AU2003257850A8 (en) 2004-03-03
JPWO2004016655A1 (ja) 2005-12-02

Similar Documents

Publication Publication Date Title
DE60334460D1 (de) Antikörper spezifisch für das tau-protein des zentralen nervensystems
IL262513A (en) Cleaning proteins
EP1693448A4 (de) Doppelt spezifische antikörper als ersatz für funktionelles protein
NO20043564L (no) Follistatindomene som inneholder proteiner
ATE480567T1 (de) Hochkonzentrierter antikörper und proteinformulierungen
DE60330692D1 (de) Kontrollsystem für eine gehhilfe
DE602004007497D1 (de) System und verfahren für umgekehrte umlaufzementierung
HK1077836A1 (en) Method of purifying protein
ATE465180T1 (de) Therapeutische anti-igfr1-antikörper- kombinationen
EP1642109A4 (de) Verfahren zur durchführung von tests auf enzymaktivität an protein-mikroarrays
ZA200409186B (en) Specific antibodies to amyloid beta peptide, pahrmaceutical compositions and methods of use thereof.
DK1694705T3 (da) Interleukin-10-antistoffer
BRPI0413495A (pt) reagentes de peptìdeos especìficos para prìons e seus usos
AU2003209059A1 (en) Human monoclonal antibodies against membrane proteins
IS8308A (is) Amínósýrur með sækni fyrir a2o prótíninu
ATE323680T1 (de) 7-arylsulfonamid-2,3,4,5-tetrahydro-1h- benzo¬däazepine mit 5-ht6 rezeptor affinität zur behandlung von zentralnervensystemerkrankungen
DK1456404T3 (da) Fremgangsmåde til at bestemme difibrotids biologiske aktivitet
ATE316577T1 (de) Das goodpasture-antigen bindende protein
EP1666588A4 (de) Neuartiges transporter protein
GB0314856D0 (en) Protein expression system
DE60222149D1 (de) Referenzkontrolle für hochempfindliche tests des c-reaktiven proteins
ATE510906T1 (de) Kv10.1, ein neuer potential-abhängiger kaliumkanal des menschlichen gehirns
EP1700114A4 (de) Verfahren zur anreicherung/abtrennung eines proteins oder peptids
DE60215226D1 (de) Methode für die isolierung von dna
PL376745A1 (pl) Proces oczyszczania białek wiążących TNF przy użyciu IMAC